Trials / Terminated
TerminatedNCT01262690
A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin
A Phase 1 Ascending Single Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-05230901 Administered Subcutaneously To Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This study will examine whether a single dose of PF-05230901 is safe and well tolerated when given to healthy volunteers by injection under the skin. An additional objective is to measure the blood concentrations of PF-05230901. Each dose will be tested in a different group of subjects starting from the lowest dose.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-05230901 | Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo. |
| DRUG | PF-05230901 | Single dose SC |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2011-09-01
- Completion
- 2011-09-01
- First posted
- 2010-12-17
- Last updated
- 2011-10-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01262690. Inclusion in this directory is not an endorsement.